Clinical Trials

Below is a listing of clinical trials conducted at MUSC Hollings Cancer Center. Use the tools in the left toolbar to refine your search. If you are interested in Early Phase/Multi Tumor trials, select the program “Phase I Unit.” Please note that cohort information for the Phase I trials changes often.

Clinical Research Group Intranet
Hold Ctrl (Cmd on Mac) to select multiple.
Protocol Title Status Docs
104286 A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer OPEN TO ACCRUAL

104245 A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer OPEN TO ACCRUAL

104112 A Phase 3, Multi-center, Double-blind, 2-part Study in Participants with KRAS G12C-Mutant, Non-Small Cell Lung Cancer Comparing the Efficacy and Safety of Olomorasib in Combination with Standard of Care to Placebo in Combination with Standard of Care as Adjuvant Treatment after Platinum-based Chemotherapy OPEN TO ACCRUAL

103883 A feasibility and Randomized phase 2/3 study of the VEFGR2/MET inhibitor Cabozanitinib in combination with cytotoxic chemotherapy for newly diagnosed osteosarcoma OPEN TO ACCRUAL

104285 A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer OPEN TO ACCRUAL

104262 TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination with Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination with Darolutamide Versus Darolutamide Alone in Patients with Metastatic Hormone Sensitive Prostate Cancer OPEN TO ACCRUAL

104248 A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) OPEN TO ACCRUAL

103878 A Prospective, Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma OPEN TO ACCRUAL

104360 A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients OPEN TO ACCRUAL

104082 A Phase 1, open-label, dose-escalation and dose-expansion study evaluating AO-252, a protein-protein interaction inhibitor of TACC3, in patients with advanced solid tumors with or without brain metastases OPEN TO ACCRUAL

104225 An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer. OPEN TO ACCRUAL

104333 A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS) OPEN TO ACCRUAL

104250 A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy OPEN TO ACCRUAL

104270 Omission of Post-Operative Radiation in Patients with Intermediate Pathological Risk Features and Negative Two Week Post-Operative ctHPVDNA (OPERATION Trial) OPEN TO ACCRUAL

104177 A Phase III, Open-Label, Multi-Center, Randomized Study Comparing AAA817 Plus ARPI Versus Standard of Care in Adult Participants with PSMA-Positive Metastatic Castration Resistant Prostate Cancer OPEN TO ACCRUAL

104156 A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-nave Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL) OPEN TO ACCRUAL

104241 A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination with Immune Checkpoint Inhibition in Participants with Locally Advanced or Metastatic Refractory Solid Tumors OPEN TO ACCRUAL

104243 A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma OPEN TO ACCRUAL

104085 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy of Visugromab in Combination with Pembrolizumab, Pemetrexed, and Cis- /Carboplatin in Participants with Newly Diagnosed Metastatic Non-Squamous Non-Small Cell Lung Cancer OPEN TO ACCRUAL

104205 A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis OPEN TO ACCRUAL